Hear from a panel of leading Australian pharmacists as they discuss their views and insights around the use of biosimilar medicines
This activity will take approximately one hour to complete and includes reflection questions.
Upon completion of this activity, participants will be able to:
Outline the clinical development and regulatory processes required prior to approval of biosimilar medicines
Explain to patients what a biosimilar medicine is, why it is different to a generic medicine, and their therapeutic equivalence to the reference biological product
Explain how biosimilar medicines contribute to the sustainability of the Australian healthcare system
This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan.
Accreditation number: CX20070